The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Previous Top Honorees are not eligible for nomination. Remaining honorees are eligible. 2019 Not-For-Profit/Government Todd Davis, Hendricks Regional Health Steve Herriford, University of Indianapolis Peter Williams, Butler University – Top Honoree Private Company — Under $100M Joe Gadell, GadellNet Consulting Services Curt Knapp, Perq – Top Honoree Alan Pyrz, eGov Strategies Private Company — Over […]
The Fishers Redevelopment Commission approved a resolution Monday that would allow the city to sublease space in the Meyer Najem headquarters on Lantern Road to 12 Stars Media.
Mike Meadows helped with the massive task of taking Lilly’s IT organization through a downsizing that reduced expenses about 40 percent—with no significant IT service disruptions.
Wheaton has bought a string of companies, including Bekins Van Lines, which required Jarrod Carter and his team to make a series of imporant decisions about which technology systems to ditch or adapt.
A jury found Lilly isn't liable for withdrawal symptoms experienced by a woman who quit the antidepressant Cymbalta. The verdict may give the drugmaker leverage in fending off more than 5,000 other lawsuits over the drug.
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
Innovative thinking can help Indiana maintain its leadership in the life sciences, can boost Indiana’s economy, and can bring even more important medical breakthroughs to market.
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
Eli Lilly and Co.’s highly anticipated cholesterol drug passed a “futility analysis,” allowing it to complete a critical Phase 3 study in patients, according to Reuters. The drug, called evacetrapib, is designed to boost "good" HDL cholesterol while lowering "bad" LDL cholesterol. An independent panel of scientific advisers recommended that the clinical trial of the […]
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Indy’s annual Gen Con convention has become a powerhouse in the growing $880 million international hobby game business—and a boon for homegrown gaming startups, including Plowgames.
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
Emboldened by the proposed development of a Marriott hotel, and prospects for another new hotel, the group that promotes downtown’s south side is beginning to lay the groundwork to transform the largely ignored area into a destination.
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
